# TB-500 References: The Thymosin Beta-4 Studies and FDA Sources, Cited

> TB-500 references: every study and FDA source cited across this site, with DOIs, PubMed links, and the FDA 503A pages — the full citation register for the thymosin beta-4 record.

The complete citation register behind every panel on this site — peer-reviewed studies with DOIs and PubMed links, and the FDA pages behind the regulatory record.

## About this register

Every TB-500 reference cited across this site is listed below, numbered to match the inline markers. Studies are given with authors, journal, year, DOI, and a PubMed or DOI link. Where a finding was measured on full-length thymosin beta-4 rather than the TB-500 heptapeptide, that distinction is stated in the body text that cites it. The regulatory entries point to the live FDA pages behind the 503A record [16][17][18].

## References

[1] Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004;23(18):3599-3608. https://pubmed.ncbi.nlm.nih.gov/15329672/
[2] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. https://pubmed.ncbi.nlm.nih.gov/15565145/
[3] Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. https://pubmed.ncbi.nlm.nih.gov/10469335/
[4] Morris DC, et al. A dose-response study of thymosin β4 for the treatment of acute stroke. J Neurol Sci. 2014;345(1-2):61-67. https://pubmed.ncbi.nlm.nih.gov/25060418/
[5] Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. https://pubmed.ncbi.nlm.nih.gov/22074294/
[6] Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin β4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. https://pubmed.ncbi.nlm.nih.gov/20536472/
[7] Xiong Y, et al. Neuroprotective and neurorestorative effects of thymosin β4 treatment following experimental traumatic brain injury. J Neurosurg. 2012;116(5):1081-1092. https://pubmed.ncbi.nlm.nih.gov/22324420/
[8] Morris DC, et al. Thymosin beta4 improves functional neurological outcome in a rat model of embolic stroke. Neuroscience. 2010;169(2):674-682. https://pubmed.ncbi.nlm.nih.gov/20627173/
[9] Srivastava D, Saxena A, Dimaio JM, Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci. 2010;1194:87-96. https://pubmed.ncbi.nlm.nih.gov/20536454/
[10] Evans MA, et al. Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem. 2020;27(37):6294-6305. https://pubmed.ncbi.nlm.nih.gov/31333080/
[11] Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. https://pubmed.ncbi.nlm.nih.gov/41966639/
[12] Su Y, et al. Thymosin β4 promotes zebrafish Mauthner axon regeneration by facilitating actin dynamics. BMC Biol. 2024;22(1):241. https://pubmed.ncbi.nlm.nih.gov/39443925/
[13] Wang Z, et al. Thymosin β4 increases cardiac cell proliferation, cell engraftment, and the reparative potency of mesenchymal stromal cells in a porcine model of myocardial infarction. Theranostics. 2021;11(16):7995-8011. https://pubmed.ncbi.nlm.nih.gov/34335970/
[14] Xing Y, et al. Progress on the Function and Application of Thymosin β4. Front Endocrinol (Lausanne). 2021;12:767785. https://doi.org/10.3389/fendo.2021.767785
[15] Zhu J, et al. Mechanism of thymosin β4 in ameliorating liver fibrosis via the MAPK/NF-κB signaling pathway. J Biochem Mol Toxicol. 2023;37(8):e23338. https://pubmed.ncbi.nlm.nih.gov/37211724/
[16] U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. FDA.gov (verified 2026-05-29). https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
[17] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (entry: 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; effective 2023-09-29). FDA.gov. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
[18] U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (agenda lists BPC-157, KPV, TB-500, and MOTs-C as substances being considered for inclusion on the 503A Bulks List). FDA.gov (verified 2026-05-29). https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
[19] U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act (guidance finalized January 2025). FDA.gov (verified 2026-05-29). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and

---

The TB-500 record inked panel by panel on blueprint stock — the Ac-LKKTETQ fragment stamped apart from the full-length thymosin beta-4 it is sold as, the empty human-trial panel left visible, and the FDA 503A status struck first; no clinic at the press and nothing here priced or dispensed.